Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999585 | 1.00 | NOTUM (0.47) | NOTUMTP53PLA2G1BATG4BACE | |
| SCHEMBL5005143 | 1.00 | NOTUM (0.47) | NOTUMTP53PLA2G1BATG4BACE | |
| SCHEMBL5005144 | 1.00 | NOTUM (0.47) | NOTUMTP53PLA2G1BATG4BACE | |
| SCHEMBL4999589 | 1.00 | NOTUM (0.47) | NOTUMTP53PLA2G1BATG4BACE | |
| SCHEMBL4995964 | 1.00 | NOTUM (0.47) | NOTUMTP53PLA2G1BATG4BACE | |
| SCHEMBL4993635 | 0.85 | SMN1; SMN2 (0.51) | TP53 | |
| SCHEMBL4996353 | 0.85 | SMN1; SMN2 (0.51) | TP53 | |
| SCHEMBL5005183 | 0.85 | SMN1; SMN2 (0.51) | TP53 | |
| SCHEMBL4996339 | 0.85 | SMN1; SMN2 (0.51) | TP53 | |
| SCHEMBL5002871 | 0.85 | SMN1; SMN2 (0.51) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1840126-A1 | 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | CYP11B2, CYP11B1, GRIN2A | NOTUM 4046/4885TP53 2959/4885PLA2G1B 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.